Cipladantin 50 & Cipladantin 100 50 mg, 100 mg Capsules
PDF Leaflet Revision Date: 06 December 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment and prevention of uncomplicated lower urinary tract infections.
Dosage (summary)
Adults: 50-100 mg four times daily for treatment; 50-100 mg daily for prevention.
Special Populations
- Renal impairment
- Hepatic dysfunction
- Elderly
Pregnancy & Breastfeeding
Contraindicated in late pregnancy and breastfeeding infants under 3 months.
Key Drug Interactions
- Probenecid
- Sulphinpyrazone
- Quinolones
- Carbonic anhydrase inhibitors
Contraindications
- Hypersensitivity to nitrofurantoin
- Anuria
- Oliguria
- Renal impairment
- Pregnant women at term
- Infants under 3 months
- G6PD deficiency
- Acute porphyria
Common side effects
- Nausea
- Vomiting
- Dizziness
- Peripheral neuropathy
- Pulmonary reactions
Counselling Points
- Take with food to minimize gastric upset
- Report signs of peripheral neuropathy
- Avoid driving if affected by dizziness
Serious warnings
- Risk of pulmonary reactions
- Monitor for hepatotoxicity
- Discontinue if hemolysis occurs
Important Disclaimer
The Cipladantin 50 & Cipladantin 100 50 mg, 100 mg Capsules professional information leaflet below is the property of Cipla Medpro and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
